Q32 Bio (FRA:DB0) Dividend Payout Ratio: 0.00 (As of Mar. 2026)


FRA:DB0 Q32 Bio Inc FRA:DB0
17 GF Score
Price €11.33
! 6 Warning Signs
View Full Analysis

What is Q32 Bio Dividend Payout Ratio?

Q32 Bio FRA:DB0 -0.18% 17 Dividend Payout Ratio is 0.00 as of Mar. 2026. GuruFocus rates FRA:DB0 with a GF Score™ of 17/100. The stock has 6 warning signs investors should review. Among 133 Biotechnology companies, Q32 Bio ranks worse than 751878.95% on this metric.

The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. Q32 Bio's Dividend Payout Ratio for the months ended in Mar. 2026 was 0.00.

The historical rank and industry rank for Q32 Bio's Dividend Payout Ratio or its related term are showing as below:


FRA:DB0's Dividend Payout Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 0.44
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2026-07-07), the Dividend Yield % of Q32 Bio is 0.00%.

Q32 Bio's Dividends per Share for the months ended in Mar. 2026 was €0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.


Q32 Bio (FRA:DB0) Dividend Payout Ratio Explanation

In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.


Q32 Bio Dividend Payout Ratio Related Terms


Q32 Bio Dividend Payout Ratio Historical Data

* Premium members only.

The historical data trend for Q32 Bio's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Q32 Bio Dividend Payout Ratio Chart

Q32 Bio Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Dividend Payout Ratio
0.00 0.00 0.00 0.00 0.00

Q32 Bio Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Dividend Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:DB0 vs CAMP, CDXS, KROS: Dividend Payout Ratio Comparison

For the Biotechnology subindustry, Q32 Bio's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Q32 Bio Dividend Payout Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Q32 Bio's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Q32 Bio's Dividend Payout Ratio falls into.


FRA:DB0
17GF Score
Q32 Bio Inc FRA:DB0
Dividend Payout Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Q32 Bio Dividend Payout Ratio Calculation

The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.

Q32 Bio's Dividend Payout Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Dividend Payout Ratio=Dividends per Share (A: Dec. 2025 )/ EPS without NRI (A: Dec. 2025 )
=0/ 1.253
=0.00

Q32 Bio's Dividend Payout Ratio for the quarter that ended in Mar. 2026 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Mar. 2026 )/ EPS without NRI (Q: Mar. 2026 )
=0/ -0.467
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Dividend Payout Ratio →
What does a Dividend Payout Ratio of 0.00 mean?
Q32 Bio (FRA:DB0) has a Dividend Payout Ratio of 0.00 as of Mar. 2026. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Q32 Bio and its competitors. According to the industry distribution chart, Q32 Bio ranks #999999 out of 133 companies in the Biotechnology industry.
Is Q32 Bio's Dividend Payout Ratio too high?
Q32 Bio's current Dividend Payout Ratio is 0.00. Based on the distribution chart, Q32 Bio ranks #999999 out of 133 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Q32 Bio has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Q32 Bio's Dividend Payout Ratio compare to CAMP and CDXS?
According to the Biotechnology industry distribution chart, Q32 Bio ranks #999999 out of 133 companies for Dividend Payout Ratio. This places Q32 Bio in the lower half of its industry. The industry median Dividend Payout Ratio is 0.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Payout Ratio for a Biotechnology company?
The median Dividend Payout Ratio among Biotechnology companies is 0.44, based on 133 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Payout Ratio significantly above this median, while those in the bottom quartile fall well below. However, Dividend Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Payout Ratio mean?
A high Dividend Payout Ratio can signal that a stock is expensive relative to its fundamentals. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Q32 Bio and its competitors. For the Biotechnology industry, the median Dividend Payout Ratio is 0.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Q32 Bio's current Dividend Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q32 Bio stock overvalued right now?
Q32 Bio (FRA:DB0) has a current Dividend Payout Ratio of 0.00. The current Dividend Payout Ratio is 0.00. Q32 Bio's overall GF Score™ is 17/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Payout Ratio calculated?
Dividend Payout Ratio is calculated from a company's financial statements. For Q32 Bio (FRA:DB0), the current Dividend Payout Ratio is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Q32 Bio Business Description

Other Exchanges QTTB:USA
Address 830 Winter Street, Waltham, MA, USA, 02451
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
17GF Score

Get the complete analysis for FRA:DB0

Dividend Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.33
Price